Protalix BioTherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
$0.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly33.8MTarget: 78000000 - 83000000
Elfabrio Sales (excluding milestones) Quarterly3.5MTarget: 33000000 - 35000000
Elelyso Sales QuarterlyTarget: 20000000 - 23000000
Cash, Cash Equivalents, and Short-Term Bank Deposits Quarterly51.1MTarget: Sufficient capital to fund operations for at least 12 months
Watch Items
- PRX-115 Phase 2 RELEASE Clinical Trial EnrollmentTrigger: Completion of enrollmentAction: Monitor clinical site activation and patient recruitment updates ahead of top-line results expected in H2 2027.
- Elfabrio Commercial Adoption in the EUTrigger: Market share penetration of 15% to 20% over the long termAction: Track quarterly sales updates from commercial partner Chiesi following the EC approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen.
- Regional Geopolitical and Operational RisksTrigger: Disruption to manufacturing facilities in Carmiel, IsraelAction: Verify that the company maintains its risk mitigation strategy of storing drug substance across multiple global locations.
Research as of 19 Jun 2026